Pharmaceutical

AbbVie and EvolveImmune Therapeutics sign oncology collaboration

AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop next-generation cancer biotherapeutics.

Nov 3, 2024 - 06:00
AbbVie and EvolveImmune Therapeutics sign oncology collaboration
AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop next-generation cancer biotherapeutics.
Read the original article

Tags:

Previous Article

US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle 

Next Article

EC fines Teva $502m over multiple sclerosis treatment Copaxone practices

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Shionogi secures licence for Maze’s Pompe disease treatment

Shionogi secures licence for Maze’s Pompe disease treat...

May 11, 2024

Johnson & Johnson bets heavy on AI-driven drug discovery

Johnson & Johnson bets heavy on AI-driven drug discovery

Dec 1, 2023

STAT+: Pharmalittle: U.S. Chamber sues over Medicare price negotiations; FDA seeks new supplier for scarce cancer drug

STAT+: Pharmalittle: U.S. Chamber sues over Medicare pr...

Jun 12, 2023